Mount Sinai

Articles

A Mount Sinai-Led Study Shows Early Success of a Novel Drug in Treating a Rare and Chronic Blood Cancer

March 19th 2024

In a trial led by the Icahn School of Medicine at Mount Sinai, rusfertide demonstrated the ability to control the overproduction of RBCs in polycythemia vera.

Study Reveals New Insights Into Immune System Role in Lung Cancer Risk

March 14th 2024

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.

Lung Cancer Screening Dramatically Increases Long-term Survival Rate

December 18th 2023

Diagnosing early-stage lung cancer with low-dose computed tomography screening drastically improves the survival rate of cancer patients over a 20-year period, according to a large-scale international study being presented by Mount Sinai researchers at the annual meeting of the Radiological Society of North America.

Mount Sinai Researchers Find More Than 4,700 Gene Clusters Crucial for Prognosis in 32 Cancer Types

December 16th 2023

Groundbreaking study opens new avenues for future treatment and diagnosis.

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

December 7th 2023

The Department of Immunology and Immunotherapy and the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

Ovarian Cancer: New Biological Markers Found That May Predict Which Patients Won't Respond to Chemotherapy

November 19th 2023

Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.

New RNA-based Therapy Combats Melanoma in Mouse Models

November 18th 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.

Mount Sinai Launches Clinic to Help Breast Cancer Patients in Need of Legal Services

November 17th 2023

The Mount Sinai Medical Legal Partnership, which provides legal aid to Mount Sinai Health System patients in need, has launched a clinic to help breast cancer patients navigate legal issues that arise due to their diagnoses.

Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race

November 15th 2023

A first-of-its-kind study unveils how diabetes drives multiple myeloma growth and differences in survival outcomes for Black versus white patients with both conditions

Adding Immunotherapy to Chemotherapy Regimen Improves Survival in Metastatic Bladder Cancer Patients

November 14th 2023

A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.

Learning the Language of Cells to Beat Cancer

November 12th 2023

Andrew L. Ji, MD, is working to better understand cutaneous squamous cell carcinoma —a skin cancer that is the second most common cancer in the United States and one that causes substantial morbidity, with a considerable risk for metastatic spread and death.

Mount Sinai Awarded $3.4 Million to Study Prostate Cancer in People With HIV

November 11th 2023

The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.

Advanced Bladder Cancer Patients Could Keep Their Bladder Under New Treatment Regime, Clinical Trial Shows

November 9th 2023

Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a recently published study.

Certain Per- and Polyfluoroalkyl “Forever Chemicals” Identified as Potential Risk Factor for Thyroid Cancer

November 8th 2023

Mount Sinai study is first to document association that had been hypothesized.

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

November 6th 2023

The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Miriam Merad, MD, PhD, Elected to the National Academy of Medicine for Seminal Work in Immunology and Cell Biology

November 4th 2023

Miriam Merad, MD, PhD, an esteemed immunologist at the Icahn School of Medicine at Mount Sinai, has been elected to the National Academy of Medicine in recognition of her pioneering contributions to the fields of immunology and cell biology.

Mount Sinai Achieves Highest Rating From Society of Thoracic Surgeons for Ground-Breaking Esophagectomy Program

July 11th 2023

The Mount Sinai Health System's esophagectomy program has received a three-star overall composite score from the Society of Thoracic Surgeons.

Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma

September 9th 2022

T-cell redirection therapy has shown to be effective in patients unresponsive to initial bispecific antibody treatment.